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Introduction
============

The eye and its associated tissues house an amalgam of malignancies ranging from melanoma to lymphoma. Uveal melanoma is the most common intraocular cancer in adults worldwide. It is a subtype of melanoma that involves the ciliary body, iris, or choroid and has a high tendency for metastasis, primarily to the liver \[[@REF1]\]. Ocular adnexal lymphoma is a common orbital tumor that encompasses a miscellaneous set of disorders in the lymphoid cells involving the eyelid, conjunctiva, adnexal structures, and orbital soft tissues \[[@REF2]\]. The B-cell and T-cell lymphomas originate in the immune system but can also metastasize throughout the body. Orbital and adnexal cancer originate from the skin, muscles, and nerves surrounding the eye. In general, the Hispanic population in the United States have increased impairment of vision as well as worse use of eye care \[[@REF3]\]. If left untreated, these malignancies may result in vision loss or death.

Commonly categorized as a single ethnic group and comprising 17% of the population in 2014, Hispanics are the fastest-growing population in the United States \[[@REF4]\]. Although varying Hispanic groups share a common language and endure a similar immigration experience, there exists notable heterogeneity in their socioeconomic status, culture, and genetic makeup \[[@REF5]\]. Members of shared ancestry and geographical location possess unique risks and may be susceptible to similar diseases. Understanding the diversity of the Hispanic population can lead to greater insight into their genetics.

Numerous studies in the past have shown disparities in outcomes between Hispanic and non-Hispanic groups. However, combining the distinct Hispanic groups as one broad group provides limited explanations on the determinants of such disparities in cancer research. To combat this issue, we conducted a retrospective cohort study to compare overall and cause-specific survival in patients with ocular and periocular cancer from varying Hispanic origins.

Materials and methods
=====================

Cohort

The Surveillance Epidemiology and End Results (SEER) database, a program supported by the National Cancer Institute, was used to obtain case data to perform a retrospective analysis \[[@REF6]\]. Since 1973, the SEER registries have regularly obtained statistics on patient demographics, tumor characteristics, treatment administered, and survival of cancer cases reported from 19 different U.S geographic locations. For this study, the International Classification of Diseases for Oncology (ICD-O-3) topography codes for the eye and adnexa (C69.0-9) and eyelid (C44.1) were used to identify all ocular and periocular neoplasms diagnoses between 1973 and 2015. Only primary and malignant neoplasms were included for analysis.

Data from the North American Association of Central Cancer Registries (NAACCR) Hispanic Identification Algorithm (NHIA), an algorithm that combines multiple variables to determine the Hispanic classification, was extracted from SEER to identify the specific Hispanic origin of patients included in the sample. Cases with "NHIA Surname Only" or "Spanish/Hispanic/Latino, NOS" were excluded from the analysis due to limited specificity regarding Hispanic origin. Specific Hispanic origins "Cuban" and "Dominican Republic" were excluded due to case counts less than 20. Cases with missing survival follow-up data and unknown cause-specific death classification were also excluded from the study.

Cases were generally classified first using NHIA codes as "non-Spanish-Hispanic-Latino" or "Spanish-Hispanic-Latino." Hispanic patients were then further sub-classified through NHIA Hispanic origin code using the following groupings: "Mexican," "Dominican," "Puerto Rican," "South or Central American excluding Brazil," and "Other specified Spanish/Hispanic Origin including Europe."

Variables

Extracted demographic variables included age group, race, and sex. Extracted tumor descriptive variables included tumor site, tumor histology, grade, summary stage, and laterality. Treatment variables included the use of surgery, radiotherapy, and chemotherapy. Survival variables included vital status ("alive" or "dead"), cause-specific death classification ("alive or dead of other cause" or "dead attributable to cancer diagnosis"), and survival months.

Analysis

Demographic, tumor, and treatment characteristic variables were tabulated by specific Hispanic origin and Pearson's chi-squared test was used to compare these variables between groups. All-cause and cause-specific mortality risk were calculated using unadjusted and adjusted multiple Cox regression models for general Hispanic origin and specific Hispanic origin. For all analyses, the non-Hispanic group served as the reference. Covariates for the adjusted model included age group, sex, race, tumor site, tumor histology, grade, summary stage, laterality, surgery status, radiotherapy status, and chemotherapy status. The Kaplan-Meier method was used to calculate five-year and 10-year survival for general and specific Hispanic origin. Statistical significance was determined at p \<.05. All statistical computation was conducted using the software IBM Statistical Package for the Social Sciences (SPSS) Statistics version 25 (IBM Corp., Armonk, NY).

Results
=======

Patient characteristics

Inclusion criteria were met by 19,831 cases, amongst which 19,194 patients were non-Spanish-Hispanic-Latino and 637 patients were Spanish-Hispanic Latino. The Spanish-Hispanic-Latino group was further subdivided as 398 of Mexican origin, 44 of Puerto Rican origin, 135 of South or Central American (excluding Brazil) origin, and 60 of other Spanish/Hispanic origin (including Europe origin). For the overall cohort, the mean (+/-SD) age was 57.02 (+/- 22.91) and the mean follow-up time was 98.57 (+/-93.23) months. The demographics, tumor, and treatment characteristic variables for specific ethnic origins are displayed in Table [1](#TAB1){ref-type="table"}.

###### Demographic, tumor, and treatment characteristics of patients with ocular and periocular tumors

  -------------------------------------- ------------------------------ -------------- -------------------------------------------- ----------------------------------------------------------- ------------ ------- ------- ------- ------- --------- ------- -------
                                         Hispanic Origins                                                                                                                                                                                                      
  Non-Spanish-Hispanic-Latino            Mexican                        Puerto Rican   South or Central American excluding Brazil   Other specified Spanish‎/Hispanic origin including Europe   Chi-square                                                     
  N                                      \%                             N              \%                                           N                                                           \%           N       \%      N       \%      p-value           
  Age Group                              0-59 years                     8767           45.7%                                        248                                                         62.3%        29      65.9%   79      58.5%   28        46.7%   .001
  60-74 years                            6146                           32.0%          90                                           22.6%                                                       11           25.0%   37      27.4%   19      31.7%             
  75+ years                              4281                           22.3%          60                                           15.1%                                                       4            9.1%    19      14.1%   13      21.7%             
  Race                                   White                          16795          87.5%                                        396                                                         99.5%        44      100%    132     97.8%   60        100%    .001
  Black                                  934                            4.9%           1                                            0.3%                                                        0            0.0%    3       2.2%    0       0.0%              
  Other                                  1083                           5.6%           1                                            0.3%                                                        0            0.0%    0       0.0%    0       0.0%              
  Unknown                                382                            2.0%           0                                            0.0%                                                        0            0.0%    0       0.0%    0       0.0%              
  Sex                                    Female                         9180           47.8%                                        196                                                         49.2%        27      61.4%   75      55.6%   36        60.0%   0.038
  Male                                   10014                          52.2%          202                                          50.8%                                                       17           38.6%   60      44.4%   24      40.0%             
  Tumor Site                             Conjunctiva                    2276           11.9%                                        78                                                          19.6%        3       6.8%    31      23.0%   8         13.3%   .001
  Cornea, NOS                            152                            0.8%           9                                            2.3%                                                        2            4.5%    2       1.5%    0       0.0%              
  Retina                                 1509                           7.9%           55                                           13.8%                                                       7            15.9%   11      8.1%    13      21.7%             
  Choroid                                6975                           36.3%          81                                           20.4%                                                       8            18.2%   30      22.2%   16      26.7%             
  Ciliary body                           1363                           7.1%           12                                           3.0%                                                        5            11.4%   1       0.7%    1       1.7%              
  Lacrimal gland                         765                            4.0%           25                                           6.3%                                                        3            6.8%    15      11.1%   2       3.3%              
  Orbit, NOS                             2450                           12.8%          70                                           17.6%                                                       6            13.6%   30      22.2%   6       10.0%             
  Overlapping lesion of eye and adnexa   245                            1.3%           2                                            0.5%                                                        0            0.0%    1       0.7%    1       1.7%              
  Eye, NOS                               896                            4.7%           12                                           3.0%                                                        3            6.8%    2       1.5%    4       6.7%              
  Eyelid                                 2563                           13.4%          54                                           13.6%                                                       7            15.9%   12      8.9%    9       15.0%             
  Cancer Histology                       Adenomas and adenocarcinomas   360            1.9%                                         8                                                           2.0%         1       2.3%    4       3.0%    3         5.0%    .001
  Adnexal and skin appendage neoplasms   965                            5.0%           18                                           4.5%                                                        3            6.8%    4       3.0%    3       5.0%              
  Cystic mucinous and serous neoplasms   176                            0.9%           1                                            0.3%                                                        0            0.0%    0       0.0%    0       0.0%              
  Nevi and melanomas                     10597                          55.2%          138                                          34.7%                                                       16           36.4%   42      31.1%   27      45.0%             
  Malignant lymphomas                    3719                           19.4%          94                                           23.6%                                                       10           22.7%   44      32.6%   9       15.0%             
  Other                                  3377                           17.6%          139                                          34.9%                                                       14           31.8%   41      30.4%   18      30.0%             
  Grade                                  Grade I‎/II                    1286           6.7%                                         39                                                          9.8%         5       11.4%   14      10.4%   4         6.7%    .001
  Grade III‎/IV                          827                            4.3%           39                                           9.8%                                                        3            6.8%    6       4.4%    4       6.7%              
  Lymphomas                              2815                           14.7%          79                                           19.8%                                                       9            20.5%   36      26.7%   7       11.7%             
  Unknown                                14266                          74.3%          241                                          60.6%                                                       27           61.4%   79      58.5%   45      75.0%             
  Summary stage                          Localized                      2659           13.9%                                        66                                                          16.6%        8       18.2%   35      25.9%   8         13.3%   .001
  Regional                               194                            1.0%           10                                           2.5%                                                        0            0.0%    1       0.7%    0       0.0%              
  Distant                                424                            2.2%           12                                           3.0%                                                        0            0.0%    5       3.7%    1       1.7%              
  Unknown‎/unstaged                      15917                          82.9%          310                                          77.9%                                                       36           81.8%   94      69.6%   51      85.0%             
  In situ                                0                              0.0%           0                                            0.0%                                                        0            0.0%    0       0.0%    0       0.0%              
  Laterality                             Unilateral                     18235          95.0%                                        373                                                         93.7%        41      93.2%   129     95.6%   54        90.0%   0.268
  Bilateral                              680                            3.5%           23                                           5.8%                                                        3            6.8%    5       3.7%    5       8.3%              
  Paired site, but unknown laterality    246                            1.3%           2                                            0.5%                                                        0            0.0%    1       0.7%    1       1.7%              
  Not a paired site                      33                             0.2%           0                                            0.0%                                                        0            0.0%    0       0.0%    0       0.0%              
  Radiation Status                       No‎/Unknown                    11234          58.5%                                        260                                                         65.3%        34      77.3%   75      55.6%   42        70.0%   0.002
  Yes                                    7960                           41.5%          138                                          34.7%                                                       10           22.7%   60      44.4%   18      30.0%             
  Surgery Status                         Not performed                  7977           41.6%                                        129                                                         32.4%        7       15.9%   53      39.3%   16        26.7%   .001
  Performed                              10917                          56.9%          264                                          66.3%                                                       35           79.5%   79      58.5%   43      71.7%             
  Unknown                                300                            1.6%           5                                            1.3%                                                        2            4.5%    3       2.2%    1       1.7%              
  Chemotherapy status                    No‎/Unknown                    17100          89.1%                                        321                                                         80.7%        36      81.8%   117     86.7%   47        78.3%   .001
  Yes                                    2094                           10.9%          77                                           19.3%                                                       8            18.2%   18      13.3%   13      21.7%             
  -------------------------------------- ------------------------------ -------------- -------------------------------------------- ----------------------------------------------------------- ------------ ------- ------- ------- ------- --------- ------- -------

Survival outcomes

After adjustment for confounding covariates, Spanish-Hispanic-Latino patients had significantly increased all-cause (HR, 1.173; 95% CI 1.022-1.347; P = 0.023) and cancer-specific mortality (HR, 1.328; 95% CI 1.099-1.604; P = 0.003) compared to their non-Spanish-Hispanic-Latino counterparts. In an adjusted sub-analysis compared to a non-Spanish-Hispanic-Latino background, patients of Mexican origin had significantly increased all-cause (HR, 1.229; 95% CI 1.032-1.464; P = 0.021) and cancer-specific mortality (HR, 1.516; 95% CI 1.204-1.909; P \< .001) and patients with other Hispanic/Spanish origin, including Europe, had significantly increased all-cause (HR, 1.627; 95% CI 1.16-2.28; P =0.005) but not cancer-specific (HR, 1.243; 95% CI 0.734-2.104; P = 0.418) mortality. Patients with Puerto Rican origin and South or Central American (excluding Brazil) origin had no significant difference in all-cause or cancer-specific mortality compared to those of non-Spanish-Hispanic-Latino origin (Table [2](#TAB2){ref-type="table"}). Kaplan-Meier survival rates at 5- and 10-year follow-up are displayed in Table [3](#TAB3){ref-type="table"}.

###### Unadjusted and adjusted Cox regression analysis

  ---------------------------------------------------------- ----------------------------- ------------------------- ---------------------- ----------- -----------
                                                             Overall survival              Cause-specific survival                                      
  HR (95% CI)                                                p-value                       HR (95% CI)               p-value                            
  Unadjusted analysis                                        Non-Spanish-Hispanic-Latino   reference                 reference              reference   reference
  Hispanic                                                   0.916 (0.798, 1.05)           0.207                     0.997 (0.827, 1.203)   0.978       
  Adjusted analysis                                          Non-Spanish-Hispanic-Latino   reference                 reference              reference   reference
  Hispanic                                                   1.173 (1.022, 1.347)          0.023\*                   1.328 (1.099, 1.604)   0.003\*     
  Unadjusted analysis                                        Non-Spanish-Hispanic-Latino   reference                 reference              reference   reference
  Mexican                                                    0.952 (0.8, 1.133)            0.581                     1.113 (0.885, 1.398)   0.36        
  Puerto Rican                                               1.036 (0.652, 1.645)          0.881                     1.293 (0.716, 2.337)   0.395       
  South or Central American excluding Brazil                 0.565 (0.393, 0.814)          0.002\*                   0.515 (0.299, 0.888)   0.017\*     
  Other specified Spanish/Hispanic Origin including Europe   1.348 (0.963, 1.888)          0.082                     1.152 (0.682, 1.947)   0.596       
  Adjusted analysis                                          Non-Spanish-Hispanic-Latino   reference                 reference              reference   reference
  Mexican                                                    1.229 (1.032, 1.464)          0.021\*                   1.516 (1.204, 1.909)   .001        
  Puerto Rican                                               1.454 (0.915, 2.312)          0.113                     1.671 (0.923, 3.025)   0.09        
  South or Central American excluding Brazil                 0.711 (0.494, 1.025)          0.067                     0.734 (0.425, 1.266)   0.266       
  Other specified Spanish/Hispanic Origin including Europe   1.627 (1.16, 2.28)            0.005\*                   1.243 (0.734, 2.104)   0.418       
  ---------------------------------------------------------- ----------------------------- ------------------------- ---------------------- ----------- -----------

###### Kaplan-Meier 5-year and 10-year survival rates.

  ---------------------------------------------------------- ----------------------------- ------------------------- --------------- ------- -------
                                                             Overall Survival              Cause-specific survival                           
  5yr survival                                               10yr survival                 5yr survival              10yr survival           
  General                                                    Non-Spanish-Hispanic-Latino   73.7%                     57.5%           83.6%   75.5%
  Hispanic                                                   76.4%                         61.4%                     85.1%           78.0%   
  Specific Origin                                            Non-Spanish-Hispanic-Latino   73.7%                     57.5%           83.6%   75.5%
  Mexican                                                    75.2%                         62.9%                     84.6%           76.1%   
  Puerto Rican                                               76.3%                         58.5%                     81.7%           72.6%   
  South or Central American Excluding Brazil                 85.8%                         70.5%                     91.1%           87.7%   
  Other specified Spanish/Hispanic Origin Including Europe   66.1%                         42.1%                     79.2%           73.5%   
  ---------------------------------------------------------- ----------------------------- ------------------------- --------------- ------- -------

Discussion
==========

There is appreciable heterogeneity in ocular and periocular mortality within the Hispanic population. The Spanish-Hispanic-Latino population had greater all-cause and cancer-specific mortality than their non-Spanish-Hispanic-Latino counterparts. Through further analysis, we found significant differences in survival by specific Spanish-Hispanic-Latino origin.

Relative to non-Spanish-Hispanic-Latino patients, patients of Mexican origin demonstrated increases in both cancer-specific and all-cause mortality. Patients of Puerto Rican origin and South or Central American (excluding Brazil) origin demonstrated no difference in all-cause and cancer-specific mortality relative to non-Spanish-Hispanic-Latino. Importantly, although patients of other Hispanic/Spanish origin, including Europe, demonstrated an increase in all-cause mortality, they possessed no difference in cancer-specific mortality; this finding may be explained due to an increase in mortality unrelated to the primary cancer itself (i.e., cardiovascular disease). Our results demonstrate that Hispanic subgroups possess differing levels of disease burdens, likely due to multiple factors, including genetic heterogeneity and health disparities. 

Our findings are consistent with other studies of varying anatomical regions and cancer histology, which found that the Hispanic population is at higher risk for malignancies and related complications (i.e., mortality) \[[@REF7]-[@REF10]\]. Studies such as the Los Angeles Latino Eye Study have attempted to quantify risk factors for ocular conditions in the Hispanic population at large, but sparse literature exists on the effect of genetic and ancestral variation on such conditions, specifically ocular and periocular malignancies \[[@REF11]\]. Our study highlights which of the specific subsets of the Hispanic population are most vulnerable to disparities in ocular and periocular neoplasms. We did not find significant differences in all-cause and cause-specific mortality in the Puerto Rican origin populations as found by previous studies \[[@REF12]\]. Risk factors for lung, colon, and hepatic malignancies addressed by these studies such as smoking and alcohol use are more prevalent in the Puerto Rican origin population in relation to other Hispanic subgroups \[[@REF12]-[@REF13]\]. However, risk factors for uveal melanoma, including fair skin, are not significantly increased in this subset \[[@REF14]\]. Ocular adnexal lymphoma risk factors, such as certain infectious agents, have not been studied in the American Hispanic population \[[@REF15]\]. Given the genetic heterogeneity between Hispanic populations of varying origin, when these patients develop ocular and periocular malignancies, they may be genetically predisposed to less advanced disease, and, therefore, possess lower mortality related to the disease \[[@REF1]-[@REF2]\]. These key differences between ophthalmologic malignancies and non-ophthalmologic malignancies may account for differences in our findings regarding patients of Puerto Rican Hispanic origin.

It is possible that our findings may have been influenced by the lower socioeconomic status of the Spanish-Hispanic-Latino population of the U.S. in comparison to the non-Spanish-Hispanic-Latino population, a variable which the database is limited in accounting for \[[@REF16]\]. However, additional insight can be offered by prior studies. Higher levels of education and socioeconomic status are indicators of general eye health knowledge, crucial for the early detection of malignancies \[[@REF3],[@REF17]\]. Among the groups studied, the Puerto Rican origin subset has the highest rates of completion of high school \[[@REF16]\]. In contrast, individuals of Mexican origin in the U.S. have been found to have 5% and 31.2% lower high school completion rates than all Hispanic groups and non-Hispanic white groups respectively \[[@REF16]\]. Level of education may, therefore, contribute to the lack of significant difference in all-cause and cause-specific mortality in patients of Puerto Rican origin as well as the increased all-cause and cause-specific findings in patients of Mexican origin.

Our findings may also reflect disparities in healthcare access (i.e. adherence to routine preventative eye care). The Hispanic population is more than twice as likely to be uninsured than the non-Hispanic white population, placing a great strain on access to needed early interventions \[[@REF18]\]. Compared to non-Hispanic whites, Hispanics had lower levels of glycated hemoglobin (HbA1c) testing, eye exams, and other preventative health screenings \[[@REF19]\]. Compared to patients of Central/South American origin, patients of Mexican origin had lower levels of preventative cancer screening for cervical (3% lower), breast (6% lower), and colorectal (6% lower) cancers \[[@REF13]\]. Similarly, decreases were found when comparing screening test use in patients of Mexican origin to those of Puerto Rican origin for breast (2% lower), cervical (6% lower), and colorectal (16% lower) cancers \[[@REF13]\]. Patients who receive decreased age-specific preventative cancer screening are likely to have decreased healthcare access and, therefore, may have disease detected at more advanced stages and poorer adherence to treatment regimens.

The Hispanic population in the United States consists of diverse subcategories that may be subject to various genetic predispositions tracing back to common ancestry and origins of location \[[@REF5],[@REF20]-[@REF21]\]. This may manifest beyond the scope of malignancies as well \[[@REF22]\]. It is important to identify these differences with regard to both ophthalmological and broader health conditions to effectively treat this rapidly growing demographic. Focusing future studies on specified population parameters will help us understand the factors behind the failure or success of treatment. As the treatment of malignancies is shifting toward targeted genetic therapies, it is becoming increasingly crucial to further analyze the demographic nature of these abnormalities.

Our study encountered multiple limitations. As the study utilized a national database, we are reliant on the data that is contained within it. Several variables, such as stage and grade, were not available for all patients included in the study, which may have confounded our findings. SEER also does not provide individual-level data regarding socioeconomic status (SES), education attainment, comorbidities, and modifiable risk factors (i.e., obesity, smoking), limiting our ability to account for those variables; identifying high-risk populations is still an important first step, however. Importantly, despite using a national database, our study was limited in sample size, which led to the exclusion of important subgroup origins (i.e. Cuban origin). Our study may also be limited by potential type II errors, causing real differences to not be detected. Due to the nature of our study, additional limitations included disease progression from the presentation, limited treatment data, and a possibility for miscoding. Despite these limitations, however, the SEER database has been validated for such studies.

Conclusions
===========

Mortality risk following ocular and periocular cancer diagnoses varies extensively by Spanish-Hispanic-Latino sub-ethnicity when compared to non-Spanish-Hispanic-Latino patients. Understanding differences in disease manifestation is important to identify vulnerable populations and develop effective management plans in order to optimize long-term patient outcomes.
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